Intravesical Therapy News and Research

RSS
Intravesical therapy is widely used in practice as an adjuvant treatment for early stage bladder cancer, following surgical transurethral resection. This is because it is a localized treatment that is administered directly into the bladder, leading to fewer systemic side effects but reduced efficacy on any metastases throughout the body.
Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

Johns Hopkins Greenberg Bladder Cancer Institute awards grants for 10 bladder cancer research projects

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Instillation of chemotherapy can minimize recurrence and progression of bladder cancer

Instillation of chemotherapy can minimize recurrence and progression of bladder cancer

Patients with high-grade noninvasive bladder cancer do not receive recommended care

Patients with high-grade noninvasive bladder cancer do not receive recommended care

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

More intensive treatment not associated with better outcomes in early bladder cancer

More intensive treatment not associated with better outcomes in early bladder cancer

New guidelines on non-muscle invasive bladder cancer

New guidelines on non-muscle invasive bladder cancer